We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed at $42.73 in the latest trading session, marking a +0.85% move from the prior day. This move lagged the S&P 500's daily gain of 1.07%. Elsewhere, the Dow gained 0.65%, while the tech-heavy Nasdaq added 1.71%.
Coming into today, shares of the drugmaker had lost 1.72% in the past month. In that same time, the Medical sector lost 2.4%, while the S&P 500 lost 0.58%.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be January 29, 2019. The company is expected to report EPS of $0.63, up 1.61% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $13.77 billion, up 0.48% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for PFE. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.19% lower within the past month. PFE is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, PFE currently has a Forward P/E ratio of 13.85. Its industry sports an average Forward P/E of 14.41, so we one might conclude that PFE is trading at a discount comparatively.
Also, we should mention that PFE has a PEG ratio of 2.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.9 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 29, which puts it in the top 12% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Gains But Lags Market: What You Should Know
Pfizer (PFE - Free Report) closed at $42.73 in the latest trading session, marking a +0.85% move from the prior day. This move lagged the S&P 500's daily gain of 1.07%. Elsewhere, the Dow gained 0.65%, while the tech-heavy Nasdaq added 1.71%.
Coming into today, shares of the drugmaker had lost 1.72% in the past month. In that same time, the Medical sector lost 2.4%, while the S&P 500 lost 0.58%.
Wall Street will be looking for positivity from PFE as it approaches its next earnings report date. This is expected to be January 29, 2019. The company is expected to report EPS of $0.63, up 1.61% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $13.77 billion, up 0.48% from the prior-year quarter.
Investors should also note any recent changes to analyst estimates for PFE. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.19% lower within the past month. PFE is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, PFE currently has a Forward P/E ratio of 13.85. Its industry sports an average Forward P/E of 14.41, so we one might conclude that PFE is trading at a discount comparatively.
Also, we should mention that PFE has a PEG ratio of 2.07. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.9 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 29, which puts it in the top 12% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.